Our new whitepaper explores how conventional treatments (surgical and medicine-based) tackle existing challenges of the conditions, and the limitations they face.
Glaucoma screening: a global perspective
What are the risk factors for glaucoma and how can identifying them guide creation of robust screening programmes?
60 million people live with glaucoma worldwide, and close to 5 million people are blind from open angle glaucoma. Glaucoma is prevalent and presents many challenges for the eye health industry. Our whitepaper examines open angle and angle closure glaucoma from a global perspective , looking at:
- The prevalance of glaucoma
- Genetic and age-related risk factors
- Glaucoma screening in practice
Age-related macular degeneration: the case for early screening
Our whitepaper explores the development of AMD and helps you to understand the key risk factors. Our analysis spans non-modifiable risk factors such as family history and genetic, as well as modifiable factors like smoking, diet and BMI.
Read our paper for insights into:
- The academic case for targeted screening
- Lifestyle factors affecting AMD development
- Understanding wet and dry AMD
- How ophthalmologists can raise awareness of AMD
The use of MPS ll as part of a macular screening programme
Prevention is better than intervention
This whitepaper outlines pragmatic guidelines for a coherent strategy around the prevention and management of age-related macular degeneration (AMD).
Written by Dr. Scott Mackie, a Consultant Ophthalmologist, supported by Elektron Eye Technology.